Migrastatics: Redirecting R&D in Solid Cancer Towards Metastasis?
Language English Country United States Media print-electronic
Document type Journal Article, Research Support, Non-U.S. Gov't, Review
Grant support
24478
Cancer Research UK - United Kingdom
C33043/A24478
Cancer Research UK - United Kingdom
PubMed
31813449
DOI
10.1016/j.trecan.2019.10.011
PII: S2405-8033(19)30204-3
Knihovny.cz E-resources
- Keywords
- cancer therapy, invasiveness, metastasis, migrastatic treatment,
- MeSH
- Neoplasm Invasiveness genetics MeSH
- Humans MeSH
- Neoplasm Metastasis MeSH
- Cell Line, Tumor MeSH
- Neoplasms complications MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Review MeSH
The concept of 'migrastatics' allows the development of a new drug class that is neither cytotoxic nor antiproliferative but is solely directed towards inhibition of cancer cell motility. Given that the regulatory pathway is open, and migrastatic candidates have been described, it is the right time to enter a new era of antimetastatic treatment.
References provided by Crossref.org
Synthesis and migrastatic activity of cytochalasin analogues lacking a macrocyclic moiety
The emerging role of microtubules in invasion plasticity
Circulating Tumour Cells (CTCs) in NSCLC: From Prognosis to Therapy Design
Are We Ready for Migrastatics?
Complex Interplay of Genes Underlies Invasiveness in Fibrosarcoma Progression Model
Interleukin-6: Molecule in the Intersection of Cancer, Ageing and COVID-19
